Patents by Inventor Johannes Hebebrand

Johannes Hebebrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING ANOREXIA NERVOSA AND RELATED CONDITIONS BY ADMINISTERING A LEPTIN RECEPTOR AGONIST
    Publication number: 20230080196
    Abstract: The invention concerns methods for treating unwanted body weight loss, and/or medically undesired body weight loss, or eating disorders (such as anorexia nervosa), by administration of a leptin receptor agonist, such as metreleptin. The invention also relates to methods for increasing body weight in a subject in need of the treatment.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 16, 2023
    Inventors: Johannes HEBEBRAND, Jochen ANTEL
  • Method of preparing pharmaceutical compositions
    Patent number: 7282325
    Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: October 16, 2007
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske
  • Method of treating or inhibiting obesity
    Patent number: 7238470
    Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: July 3, 2007
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske
  • Use of SNPs of MCH-R for identifying genetic disorders in maintaining the normal body weight
    Publication number: 20050233372
    Abstract: A process for identification of a human individual's disposition for a genetic disorder in maintaining body weight is disclosed.
    Type: Application
    Filed: June 17, 2005
    Publication date: October 20, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Johannes Hebebrand, Anke Hinney, Anne-Kathrin Wermter, Frank Geller, Andreas Ziegler
  • Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
    Patent number: 6946243
    Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: September 20, 2005
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske
  • Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
    Publication number: 20040167214
    Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 26, 2004
    Applicant: Solvay Pharmaceuticals GmbH
    Inventors: Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske
  • Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
    Publication number: 20040167213
    Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 26, 2004
    Applicant: Solvay Pharmaceuticals GmbH
    Inventors: Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske
  • Use of SNPs of MCH-R for identifying genetic disorders in maintaining the normal body weight
    Publication number: 20030157511
    Abstract: A process for identification of a human individual's disposition for a genetic disorder in maintaining body weight is disclosed.
    Type: Application
    Filed: August 21, 2002
    Publication date: August 21, 2003
    Inventors: Johannes Hebebrand, Anke Hinney, Anne-Kathrin Wermter, Frank Geller, Andreas Ziegler
  • Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
    Publication number: 20020022245
    Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.
    Type: Application
    Filed: July 18, 2001
    Publication date: February 21, 2002
    Inventors: Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske